Bloomberg Law
How Life Sciences Firms Can Reduce DOJ Enforcement Risks
May 6, 2021
The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.
Contacts
Related Blogs
Capabilities
Suggested News & Insights
Court Grants Summary Judgment in Kickback-Based FCA Case, Holding Relator Failed to Prove Remuneration or WillfulnessOctober 7, 2026False Claims Act Risk on the RadarTuesday, October 6, 2026Court Holds Insurer Must Cover FCA Settlement Despite “Fraudulent Acts” ExclusionOctober 2, 2026DOJ Continues to Prioritize Medicare Advantage Enforcement with $22.5 Million SettlementOctober 1, 2026Texas Medicaid Fraud Decision Leaves 2 Open QuestionsOctober 1, 2026D.C. U.S. Attorney’s Office Announces Creation of Standalone Division Focused on False Claims Act EnforcementSeptember 25, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory